| Literature DB >> 28092347 |
L Castagna1, S Bramanti1, R Devillier2, B Sarina1, R Crocchiolo1, S Furst2, J El-Cheikh2, A Granata2, C Faucher2, S Harbi2, L Morabito1, J Mariotti1, S Puvinathan3, P J Weiller2, C Chabannon4,5,6, D Mokart7, C Carlo-Stella1,8, R Bouabdallah2, A Santoro1,9, D Blaise2,5,6.
Abstract
We investigated the use of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of advanced Hodgkin lymphoma (HL). Sixty-two consecutive HL patients underwent haplo-HSCT. Unmanipulated stem cells and post-transplant cyclophosphamide were given to all patients as GVHD prophylaxis. At 100 days, the cumulative incidence of grades 2-3 and grades 3-4 acute GVHD was 23% and 4%, respectively. The chronic GVHD (cGVHD) cumulative incidence was 16%, with one patient experiencing severe cGVHD. The 3-year OS, PFS, relapse rates and 1-year non-relapse mortality (NRM) were 63%, 59%, 21% and 20%, respectively. Uncontrolled disease status and high hematopoietic cell transplantation comorbidity index (HCT-CI) were associated with lower OS, whereas PBSC was an independent protective factor. Uncontrolled disease and HCT-CI >2 was predictive for NRM. Finally, disease status other than CR was predictive of relapse. In conclusion, haplo-HSCT is a valid treatment in advanced HL, offering excellent rates of survival and acceptable toxicities.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28092347 DOI： 10.1038/bmt.2016.348
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483